(Press-News.org) The end of pandemic-era enrollment enhancements for Medicaid was associated with a rise in the number of people ending medication treatment for opioid use disorder, as well as a decrease in the number of people beginning such treatment, according to a new RAND study.
While some people who disenrolled from Medicaid may have found other methods to pay for drug treatment, the overall number of those initiating and continuing medication treatment for opioid use disorder declined in the six months after Medicaid unwinding began. The changes were greatest in states that have had the largest disenrollments.
The study tracked treatment episodes of the opioid use disorder medication buprenorphine from 2021 to 2023 as pandemic-era Medicaid enrollment protections were phased out. The study authors say the findings have relevance given the recent federal legislation expected to result in 10 million Americans losing their Medicaid health coverage by 2034.
The study is published in the Journal of Addiction Medicine.
“These findings are particularly salient at a time when policy changes are increasing uncertainty about Medicaid coverage for many individuals,” said Bradley D. Stein, the study’s corresponding author and a senior physician policy researcher at RAND, a nonprofit research organization. “To sustain progress the nation has made against the opioid overdose crisis, it is essential to ensure that individuals who can benefit from life-saving medication continue to receive it.”
Medication treatment is the most-effective treatment for people battling addiction to fentanyl and other opioids, with buprenorphine being one commonly prescribed treatment for individuals with opioid use disorder. Medicaid covers approximately 40% of treatment for Americans with opioid use disorder.
More than 25 million Americans have disenrolled from Medicaid as a result of Medicaid unwinding -- the process in which states resumed normal Medicaid enrollment procedures after a period of continuous coverage mandated during the COVID-19 pandemic.
To examine the role that unwinding played in medication treatment for opioid use disorder, RAND researchers examined prescriptions dispensed at retail pharmacies in all 50 states and the District of Columbia to identify buprenorphine treatment episodes from Jan. 1, 2021 to Dec. 31, 2023.
About 45% of the buprenorphine treatment episodes were paid for by Medicaid, 18% by commercial insurance, 11% by Medicare, 11% by discount cards/vouchers, and 6% were cash-pay. Approximately 27% of treatment episodes were in high-unwinding states, 41% in moderate-unwinding states, and 31% in low-unwinding states.
On average, there were 3% more treatment episodes paid for by Medicaid that ended after unwinding began as compared to before unwinding. In states with the greatest unwinding, the percentage difference was more than double that in states with moderate or low levels of unwinding.
There were 2.6% fewer new treatment episodes paid for by Medicaid in the six months after unwinding compared to six months before unwinding. There was a significant 3.9% decrease in new treatment episodes paid for by Medicaid in states with the greatest unwinding, compared to a 2.4% decrease in states with moderate unwinding, and a 2% decrease in states with the smallest amount of unwinding.
Changes in treatment episodes paid for by Medicaid appear not to be completely offset by changes in reimbursement from other sources, such as individuals losing Medicaid paying out-of-pocket for buprenorphine or obtaining commercial insurance.
“These changes were associated with an increase in the number of Medicaid enrollees stopping buprenorphine treatment and a decrease in enrollees beginning it,” said Rachel K. Landis, study coauthor and policy researcher at RAND. “Consistent with research on total buprenorphine fills, effects were greatest in states with the greatest Medicaid disenrollment.”
Research reported in this press release was supported by the National Institute on Drug Abuse of the National Institutes of Health under award number P50DA04635108. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Support for the study was also provided by the Foundation for Opioid Response Efforts (FORE).
Another author of the study is Flora Sheng.
RAND Health Care promotes healthier societies by improving health care systems in the United States and other countries.
END
A team of researchers including Rice University’s James Tour and Shichen Xu has developed an ultrafast, one-step method to recover rare earth elements (REEs) from discarded magnets using an innovative approach that offers significant environmental and economic benefits over traditional recycling methods. Their study was published in the Proceedings of the National Academy of Sciences Sept. 29, 2025.
Conventional rare earth recycling is energy-heavy and creates toxic waste. The research team’s method uses flash Joule heating (FJH), which rapidly raises material temperatures to thousands of degrees within milliseconds, and chlorine gas to extract REEs from ...
SAN FRANCISCO, September 29, 2025 — The first randomized trial to compare photon- and proton-based radiation therapy for breast cancer finds that patients report equally strong health-related quality of life with either treatment. Patients who received proton therapy were more likely to say they would recommend or choose it again, but overall patient-reported outcomes were similar.
The phase III Radiotherapy Comparative Effectiveness (RadComp) trial enrolled more than 1,200 patients, making it also the largest head-to-head comparison of photon and proton therapy for any ...
SAN FRANCISCO, September 29, 2025 — For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to results of a large, randomized phase III trial. Patients treated with stereotactic body radiation therapy (SBRT) reported fewer declines in bowel, urinary and sexual functioning but were more likely to experience a rise in prostate-specific antigen (PSA). Initial results of the NRG Oncology GU005 ...
On September 5, 2020, California’s Creek Fire grew so severe that it began producing it’s own weather system. The fire’s extreme heat produced an explosive thunderhead that spewed lightning strikes and further fanned the roaring flames, making containment elusive and endangering the lives of firefighters on the ground. These wildfire-born storms have become a growing part of fire seasons across the West, with lasting impacts on air quality, weather, and climate. Until now, scientists have struggled to replicate them in Earth system models, hindering our ability to predict their occurrence ...
Embargoed for release until 5:00 p.m. ET on Monday 29 September 2025
Follow @Annalsofim on X, Facebook, Instagram, Bluesky, and Linkedin
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of ...
One in 270 Americans (nearly 1 million adults) has a BMI of 60 or greater
More than half of surveyed clinics lacked exam tables, chairs and/or gowns for patients weighing 450 pounds
Receptionists made stigmatizing comments: ‘We’ve reached our limit for bariatric patients’
Patients with obesity are less likely to get cancer screenings and preventive care
CHICAGO --- Patients weighing 450 pounds or more face barriers and discrimination when scheduling or attending doctor visits at subspecialty practices, reports a new Northwestern Medicine study.
The scientists used a “secret-shopper” method to attempt to schedule an appointment ...
Adiposity—or the accumulation of excess fat in the body—is a known driver of cardiometabolic diseases such as heart disease, stroke, type 2 diabetes, and kidney disease. But getting the full picture of a person’s risk is harder than it may seem. Traditional measures such as body mass index (BMI) are imperfect, conflating fat and muscle mass and not capturing where in the body fat is located. A new study from researchers at Mass General Brigham and their colleagues found that an AI tool designed to measure ...
Cancer cells are subjected to high mechanical pressure that leads to a rupture of the nuclear envelope when migrating through narrow tissue structures, as in the case of metastasis. DNA would normally leak out in the process, causing damage to the cell. However, researchers at the University of Freiburg’s Cluster of Excellence CIBSS - Centre for Integrative Biological Signalling Studies succeeded in demonstrating that a protective mechanism takes effect at this moment. A fine scaffold of actin filaments forms in the cell nucleus within seconds. The protein actin is a fundamental component of the cell structure. ...
EMBARGO: THIS CONTENT IS UNDER EMBARGO UNTIL 3 P.M. U.S. EASTERN STANDARD TIME ON SEPT. 29, 2025. INTERESTED MEDIA MAY RECIVE A PREVIEW COPY OF THE JOURNAL ARTICLE IN ADVANCE OF THAT DATE OR CONDUCT INTERVIEWS, BUT THE INFORMATION MAY NOT BE PUBLISHED, BROADCAST, OR POSTED ONLINE UNTIL AFTER THE RELEASE WINDOW.
Climate change is drying landscapes and raising temperatures faster than many species can adapt. A new research paper from Colorado State University offers a rare empirical look at how these pressures are already reshaping wildlife through the lens of the yellow warbler –– a ...
Researchers from Queen Mary University of London’s School of Biological and Behavioural Sciences, using the simple fission yeast as a model, have shown that new TOR inhibitor rapalink-1 prolongs chronological lifespan.
The new study, published in Communications Biology journal by Juhi Kumar, Kristal Ng and Charalampos Rallis, sheds light on how drugs and natural metabolites can influence lifespan through the Target of Rapamycin (TOR) pathway.
TOR is a conserved signalling pathway active in humans as well as yeast. It is a central regulator of growth and ageing fundamental in age-related diseases such as cancer and neurodegeneration and is already a major ...
